Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05137067 · ClinicalTrials.gov registry record · Phase 2
A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.
A Phase 2 study, sponsored by Optimal Health Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT05137067 is a Phase 2 study that has completed, run by Optimal Health Research. The registered enrollment target is 90 participants.
The verdict
NCT05137067, a Phase 2 study, has completed, sponsored by Optimal Health Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study will assess the effectiveness of a natural nutraceutical in treating the known side effects of chemotherapeutic agents in cancer patients.
Interventions
- DIETARY_SUPPLEMENT Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell)
- DRUG Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo
- DRUG Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2021-01-20 |
| Est. Completion | 2023-05-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05137067
The ClinicalTrials.gov registry entry for NCT05137067 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Optimal Health Research, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell) is the first listed.
NCT05137067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05137067 about?
NCT05137067 is a clinical study titled "A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.". This study will assess the effectiveness of a natural nutraceutical in treating the known side effects of chemotherapeutic agents in cancer patients.
What is the current status of trial NCT05137067?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2021-01-20. Estimated completion is 2023-05-25.
What interventions are being tested in trial NCT05137067?
The interventions under investigation include: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell) (DIETARY_SUPPLEMENT), Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo (DRUG), Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel). (DRUG).
Who is sponsoring clinical trial NCT05137067?
This trial is sponsored by Optimal Health Research, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.